Our Strategic Focus
Senescent cell accumulation is a key driver of aging, disrupting tissue function and promoting inflammation. Because aging is slow and not yet a defined regulatory indication, we are advancing our lead compound, SNC711, toward IND in oncology, where disease and treatment reproduce the hallmarks of aging in a rapid timeframe.
Senescent cell accumulation is a key driver of aging, disrupting tissue function and promoting inflammation. Because aging is slow and not yet a defined regulatory indication, we are advancing our lead compound, SNC711, toward IND in oncology, where disease and treatment reproduce the hallmarks of aging in a rapid timeframe.
Intellectual Property
Our lead peptide is a novel, engineered senolytic built from a core sequence that showed up consistently across our top screening hits. Twelve of fifteen hits shared the same seven–amino-acid pattern, giving us a distinct signature.
30+
Year in
business
30+
Year in
business
30+
Year in
business
This unique sequence strengthens Senvi’s IP position and creates a clear path to grow the platform with additional next-generation senolytic peptides using the same discovery and engineering framework.
Current status:
-
Provisional patent filed (Nov. 2024)- Covering peptide sequence and medical application in oncology
-
PCT application filed in 2025 to expand our global IP coverage
Our IP strategy is being lead by the renowned firm Miller Nash.
Development Plan
We are advancing SNC711 through a streamlined development path with colorectal cancer targeted for RAS or RAF mutations as our lead indication. Our plan focuses on completing key preclinical studies, achieving FDA alignment, and progressing toward first-in-human trials, while laying parallel groundwork for future indications in aging biology, metabolic and chronic disease.
Q4
Completed Lead peptide optimization
Begin in vivo PK/PD studies
Q1
Identify new molecules for the platform Pre-IND meeting with the FDA
Q2
Finalize CMC vendor selection
Q3-Q4
Initiate GMP manufacturing, Initiate IND-enabling toxicology
Q1-Q2
Initiate Phase 1/1b study (Ex-US)
Q2-Q3
Initiate US IND and Phase 1 (Oncology)
Q3-Q4
Initiate Phase 2 POC (Ophtho/Metabolism)
One Platform.Three Massive Markets.
Metabolism X Oncology X Longevity
Aging is the greatest risk factor for most chronic diseases and one of medicine's largest unmet needs.
SNC711 targets the underlying biology of aging, creating the potential for multiple firstin-class medicines across high-growth therapeutic areas.
Together, these markets could represent one of the largest blockbuster opportunities in biopharma.
Grand View Research – Obesity Treatment Market, 2025–2030 | Precedence Research – Oncology Market, 2025–2035 | Grand View Research – Senolytics & Anti-Aging Pharmaceuticals Market, 2024–2030
Our Proof of Concept
Our preclinical data shows extreme efficacy in BRAF oncogene mutations using our SNC711 as a combination therapy.
Mutations in oncogenes, like KRAS and BRAF, often result in disease with particularly high therapy resistance and mortality.
Of the 20 million people diagnosed with cancer annually, 4.6 million will have mutations in KRAS and an additional 780K patients will have BRAF mutations.
The worldwide Total Addressable Market (TAM) for therapeutics against KRAS + BRAF mutations across pancreatic, lung, melanoma and colorectal cancers exceeds $134.5 billion dollars annually.
KeyTakeaways
SENVI is developing a senolytic platform that clears harmful “zombie cells” formed after treatment and with age, helping patients respond better and recover faster.
SNC711 is a precision peptide that enters cells, removes damaged ones, and preserves healthy cells untouched.
In animal models, SNC711 combined with standard cancer therapy eliminated tumors within days and enhanced immune response
In animal models, SNC711 reduced toxic, treatmentinduced cells that drive inflammation, fatigue, and tissue damage, while showing potential to reverse aging biomarkers.
Early safety data show no liver, kidney, or blood toxicity at very high doses with a variety of delivery methods including oral, topical, and systemic.
Twelve independent hits pointed to the same peptide sequence, validating our novel discovery approach and enabling a scalable pipeline in cancer, longevity, and chronic disease.
A 2024 provisional patent protects the peptide and its cancer applications and a PCT application filed in 2025 provides global protection.
SENVI is partnering with OHSU and the Knight Cancer Institute on a cost-efficient path to FDA validation, including first-in-human studies with a lead program in colorectal cancer targeting RAS and RAF mutations.
Leadership includes world-class innovators behind landmark biotech breakthroughs, including the founder of the Human Genome Project, the developer of Gleevec, and the most cited scientist in the world from MIT.